Business Wire

MYPINPAD Achieves PCI SSC SPOC Approval for IOS Devices

7.1.2020 03:01:00 EET | Business Wire | Press release

Share

MYPINPAD (“MPP”), the global leader in secure personal authentication for payment solutions, has achieved Payment Card Industry (PCI) Security Standards Council certification for its iOS Software based PIN entry on a Commercial off-the-shelf (SPoC) solution.

The UK based fintech company is amongst the world’s first to achieve certification for its innovative PIN on Mobile solution (“MPP mPOS”), evaluated by Brightsight. The solution enables everyday smartphones and tablets to replace traditional Point of Sale terminals and PIN entry mPOS devices.

MYPINPAD’s innovative SPoC solution is seen as a major enabler for the predicted massive expansion in the number of payment acceptance devices globally. The solution is easily integrated into 3rd party applications and can be delivered ‘As-a-Service’.

The cost of hardware-based PIN pads is seen as a significant barrier to global card acceptance adoption. MPP mPOS will enable even the smallest of enterprises and those in under-served economies to accept card payments, while also relieving merchants and larger retailers from the burden of purchasing and maintaining large estates of traditional POS terminals.

Importantly, PIN entry is via a standard PIN pad image (not scrambled), ensuring seamless customer adoption. The technology supports use by people with visual impairment and people with other disabilities, which is critical in certain markets, delivering the world’s first fully inclusive solution.

Phil King, CEO and Chairman, MYPINPAD, said: “MYPINPAD has been at the forefront of the thinking about and the development of PIN on Mobile since 2012. We are proud to have achieved PCI SPoC certification for IOS devices, featuring a standard non-scrambled PIN pad that consumers trust and are familiar with. We look forward to announcing the same for Android devices soon.

Since inception MYPINPAD’s commitment to this technology has been unwavering. Our platform has been designed to make available Secure Card Reader-based and contactless payment acceptance solutions, the latter called MPP SoftPOS as a software only solution, with attestation and with the pre-integration of our code inside every payShield HSM. We look forward to being able to offer on a global basis PCI SPoC certified MPP mPOS on all devices and scheme approved MPP SoftPOS on Android devices in the new year.”

"It is a pleasure to work with the creative and skilled MYPINPAD team and help bring new and innovative payment solutions to market. We look forward in continuing our partnership with MYPINPAD in the years to come." says Rob van Marrewijk, Director Business Development at Brightsight.

***ENDS***

About MYPINPAD:

MYPINPAD is a global leader in secure personal authentication for payment solutions residing on commercially available smartphones and tablets. Our proprietary and globally patented technology secures and protects the input of sensitive information on touchscreens creating a trusted environment. MYPINPAD’s innovative solution set removes the reliance on specialised hardware for personal authentication; reduces cost and complexity, promotes rapid adoption and leverages the connected capabilities of smart devices.

Please visit www.mypinpad.com to discover more about this transformational technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Becky Sales
becky@skyparlour.com
07803204780

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye